<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01509079</url>
  </required_header>
  <id_info>
    <org_study_id>03962-10C</org_study_id>
    <nct_id>NCT01509079</nct_id>
  </id_info>
  <brief_title>Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors</brief_title>
  <official_title>Phase 2 Study Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HealthPartners Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>HealthPartners Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of this study is to determine whether vitamin D3 supplements will decrease the
      muscle and bone pain that are reported by women who take Aromatase Inhibitors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project will determine the efficacy of vitamin D3 supplements for reducing side effects
      of treatment with aromatase inhibitors in women with a history of breast cancer that have no
      evidence of current disease. The aromatase inhibitors (AI) have become a critical component
      of adjuvant therapy for this population, but they cause bone pain, joint pain, joint
      stiffness, and muscle weakness in approximately 40% of patients. These symptoms, referred to
      as aromatase inhibitor-associated musculoskeletal symptoms (AIMSS), decrease quality of life
      and medication adherence. Identifying effective ways to decrease these symptoms may allow for
      longer and more adherent medication use and thus may improve disease-free survival. We
      hypothesize that vitamin D3 may decrease symptoms associated with the use of aromatase
      inhibitors.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Musculoskeletal Symptom Sub-scale on the Breast Cancer Prevention Trial Symptom Scale</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>The MS subscale is a self-reported measure on a scale of 0 to 4, with lower score indicating less arthralgia/myalgia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Hand Grip Strength</measure>
    <time_frame>baseline to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in PROMIS Physical Functioning Questionnaire</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>PROMIS measures physical functioning on the short form and higher scores reflect better physical functioning with 10 questions on daily activities of life on a Likert scale ranging from 5 (no problem performing activity) to 1 (cannot do activity). Range on this measure is from 50 (best)-10 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Percent Adherence to Vitamin D Interventio</measure>
    <time_frame>average for all study ppts for: screening to baseline; baseline to 3 months; 3 month to 6 months</time_frame>
    <description>adherence measured with pill counts for the vitamin D at predesignated study timepoints: baseline (after run-in), 3 months and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Estradiol Concentrations</measure>
    <time_frame>baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Steady State Concentrations of Serum Anastrazole and Letrozole</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Difference in steady state concentrations in plasma from baseline to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density</measure>
    <time_frame>Change from screen to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin D Binding Protein Genotype</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Muscle Pain</condition>
  <condition>Joint Pain</condition>
  <arm_group>
    <arm_group_label>Vitamin D3 4000 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3 600 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Cholecalciferol capsule, 4000IU, daily for 6 months</description>
    <arm_group_label>Vitamin D3 4000 IU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>cholecalciferol capsule, 600 IU, daily for 6 months</description>
    <arm_group_label>Vitamin D3 600 IU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18 years

          -  Women with a history of stage I-IIIa invasive breast cancer

          -  History of hormone-receptor positive cancer (either ER + or PR + or both)

          -  Are prescribed and are taking anastrozole, letrozole or exemestane for at least one
             month and have at least 7 months of AI treatment remaining

          -  Are experiencing AIMSS

        Exclusion Criteria:

          -  Unable to read or understand English

          -  History of psychiatric disability affecting informed consent or compliance with drug
             intake

          -  Malabsorption syndrome or inability to take oral medication

          -  Has less than 7 months of AI therapy remaining
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice C. Shapiro, PhD RD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Park Nicollet Health Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Park Nicollet Frauenshuh Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Shapiro AC, Adlis SA, Robien K, Kirstein MN, Liang S, Richter SA, Lerner RE. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). Breast Cancer Res Treat. 2016 Feb;155(3):501-12. doi: 10.1007/s10549-016-3710-6. Epub 2016 Feb 11. Erratum in: Breast Cancer Res Treat. 2016 Jun;157(2):403.</citation>
    <PMID>26868123</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2011</study_first_submitted>
  <study_first_submitted_qc>January 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2012</study_first_posted>
  <results_first_submitted>August 15, 2016</results_first_submitted>
  <results_first_submitted_qc>November 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 29, 2016</results_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthralgia</mesh_term>
    <mesh_term>Myalgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D3 4000 IU</title>
          <description>Vitamin D3: Cholecalciferol capsule, 4000IU, daily for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Vitamin D3 600 IU</title>
          <description>Vitamin D3: cholecalciferol capsule, 600 IU, daily for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>started an excluded medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D3 4000 IU</title>
          <description>Vitamin D3: Cholecalciferol capsule, 4000IU, daily for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Vitamin D3 600 IU</title>
          <description>Vitamin D3: cholecalciferol capsule, 600 IU, daily for 6 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="113"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.4" spread="8.4"/>
                    <measurement group_id="B2" value="60.3" spread="9.3"/>
                    <measurement group_id="B3" value="60.9" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Musculoskeletal Symptom Sub-scale on the Breast Cancer Prevention Trial Symptom Scale</title>
        <description>The MS subscale is a self-reported measure on a scale of 0 to 4, with lower score indicating less arthralgia/myalgia</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>Only participants who provided data at both time points are included</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 4000 IU</title>
            <description>Vitamin D3: Cholecalciferol capsule, 4000IU, daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D3 600 IU</title>
            <description>Vitamin D3: cholecalciferol capsule, 600 IU, daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Musculoskeletal Symptom Sub-scale on the Breast Cancer Prevention Trial Symptom Scale</title>
          <description>The MS subscale is a self-reported measure on a scale of 0 to 4, with lower score indicating less arthralgia/myalgia</description>
          <population>Only participants who provided data at both time points are included</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.7"/>
                    <measurement group_id="O2" value="-0.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Hand Grip Strength</title>
        <time_frame>baseline to 6 months</time_frame>
        <population>only data from participants that were collected at both time points is included</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 4000 IU</title>
            <description>Vitamin D3: Cholecalciferol capsule, 4000IU, daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D3 600 IU</title>
            <description>Vitamin D3: cholecalciferol capsule, 600 IU, daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hand Grip Strength</title>
          <population>only data from participants that were collected at both time points is included</population>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="10.6"/>
                    <measurement group_id="O2" value="1.0" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PROMIS Physical Functioning Questionnaire</title>
        <description>PROMIS measures physical functioning on the short form and higher scores reflect better physical functioning with 10 questions on daily activities of life on a Likert scale ranging from 5 (no problem performing activity) to 1 (cannot do activity). Range on this measure is from 50 (best)-10 (worst).</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>only data from participants with measures at both time points are included</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 4000 IU</title>
            <description>Vitamin D3: Cholecalciferol capsule, 4000IU, daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D3 600 IU</title>
            <description>Vitamin D3: cholecalciferol capsule, 600 IU, daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PROMIS Physical Functioning Questionnaire</title>
          <description>PROMIS measures physical functioning on the short form and higher scores reflect better physical functioning with 10 questions on daily activities of life on a Likert scale ranging from 5 (no problem performing activity) to 1 (cannot do activity). Range on this measure is from 50 (best)-10 (worst).</description>
          <population>only data from participants with measures at both time points are included</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="4.9"/>
                    <measurement group_id="O2" value="1.7" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Percent Adherence to Vitamin D Interventio</title>
        <description>adherence measured with pill counts for the vitamin D at predesignated study timepoints: baseline (after run-in), 3 months and 6 months</description>
        <time_frame>average for all study ppts for: screening to baseline; baseline to 3 months; 3 month to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 4000 IU</title>
            <description>Vitamin D3: Cholecalciferol capsule, 4000IU, daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D3 600 IU</title>
            <description>Vitamin D3: cholecalciferol capsule, 600 IU, daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Average Percent Adherence to Vitamin D Interventio</title>
          <description>adherence measured with pill counts for the vitamin D at predesignated study timepoints: baseline (after run-in), 3 months and 6 months</description>
          <units>% of adherence for each treatment arm</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Estradiol Concentrations</title>
        <time_frame>baseline and 6 months</time_frame>
        <population>only participants whose serum was obtained at both time points are included</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 4000 IU</title>
            <description>Vitamin D3: Cholecalciferol capsule, 4000IU, daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D3 600 IU</title>
            <description>Vitamin D3: cholecalciferol capsule, 600 IU, daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Estradiol Concentrations</title>
          <population>only participants whose serum was obtained at both time points are included</population>
          <units>pg/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" spread="0.1"/>
                    <measurement group_id="O2" value="2.77" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94" spread="0.16"/>
                    <measurement group_id="O2" value="3.0" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Steady State Concentrations of Serum Anastrazole and Letrozole</title>
        <description>Difference in steady state concentrations in plasma from baseline to 6 months</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>Only study participants with baseline and 6 month blood samples available were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 4000 IU</title>
            <description>Vitamin D3: Cholecalciferol capsule, 4000IU, daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D3 600 IU</title>
            <description>Vitamin D3: cholecalciferol capsule, 600 IU, daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Steady State Concentrations of Serum Anastrazole and Letrozole</title>
          <description>Difference in steady state concentrations in plasma from baseline to 6 months</description>
          <population>Only study participants with baseline and 6 month blood samples available were analyzed</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>anastrozole</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="10.67"/>
                    <measurement group_id="O2" value="2.4" spread="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>letrozole</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.16" spread="9.69"/>
                    <measurement group_id="O2" value="-0.83" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Mineral Density</title>
        <time_frame>Change from screen to 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vitamin D Binding Protein Genotype</title>
        <time_frame>Baseline</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were collected with regard to the organ system</desc>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D3 4000 IU</title>
          <description>Vitamin D3: Cholecalciferol capsule, 4000IU, daily for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Vitamin D3 600 IU</title>
          <description>Vitamin D3: cholecalciferol capsule, 600 IU, daily for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal complaints</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injuries</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive and breast issues</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin problems</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Alice Shapiro</name_or_title>
      <organization>HealthPartnersInstitute</organization>
      <phone>952-993-1704</phone>
      <email>shapia@parknicollet.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

